Advances in the Lung Cancer Immunotherapy Approaches

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Lung cancer (LC) remains a leading cause of cancer death despite advances.
• LC cells exhibit low, heterogeneous antigenicity, enabling immune evasion.
• Current immunotherapies face challenges like resistance and lack of ideal predictive biomarkers.

Purpose of the Study:

• To review current lung cancer immunotherapy approaches, including clinical and preclinical trials.
• To explore the potential of immunological markers for predicting immunotherapy effectiveness.
• To discuss future directions for optimizing lung cancer treatment.

Main Methods:

• Literature review of lung cancer immunotherapy strategies.
• Analysis of clinical and preclinical trial data.
• Examination of immune evasion mechanisms and predictive biomarkers.

Main Results:

• Immune checkpoint inhibitors (ICIs) are crucial but not universally effective.
• Existing biomarkers like tumor mutation burden (TMB) and microsatellite instability (MSI) have limitations.
• Multi-parameter immune analysis offers a promising future direction for personalized treatment.

Conclusions:

• Combination strategies hold potential for lung cancer therapeutics.
• Improved patient selection and understanding of immunotherapy limitations are essential.
• Further research into novel biomarkers and combination approaches is warranted.